Anatomy and Physiology 2e · The Lymphatic and Immune System
Transplantation and Cancer Immunology
On this page 9 sections
In 30 seconds
This topic applies the "self vs. non-self" logic of immunity to two high-stakes situations. In transplantation, a surgeon deliberately places tissue from one person (or species) into another, and the recipient's immune system must be stopped from rejecting it. In cancer, the body's own cells have mutated and multiplied out of control, and the immune system — which normally tolerates self — must somehow be provoked into attacking them. Both problems revolve around the same machinery from earlier topics: MHC (called HLA Human leukocyte antigen — the human MHC molecules Full entry → in humans), T cells, antibodies, and self-tolerance. Understanding graft types, the timing and mechanisms of rejection, and the core ideas of tumor immunology (immune surveillance, Immunoediting Elimination → equilibrium → escape: the evolving relationship between tumor and immune system Full entry →, evasion, and immunotherapy) turns a list of facts into a coherent story.
Why this matters
Organ transplantation is a routine, life-saving therapy, and caring for recipients means understanding why rejection happens and why immunosuppression is a permanent trade-off (preventing rejection increases infection risk). Cancer immunology, meanwhile, is one of the fastest-moving areas of modern medicine — checkpoint inhibitors and engineered T cells are headline therapies — and every health professional will encounter their vocabulary. For exams, the graft-type hierarchy, the three rejection timelines, and the concept of immunoediting are classic high-yield items.
The college version
Core Concepts
Graft types: who donated, and how similar are they?
- Autograft Tissue moved from one site to another in the same person Full entry →: tissue moved from one site to another in the same person (e.g., a skin graft from the thigh to a burn on the arm). No rejection — it is self.
- Isograft Tissue from an identical twin Full entry →: tissue from an identical twin — genetically identical, so effectively self and not rejected.
- Allograft Tissue from a different person of the same species Full entry →: tissue from a different person of the same species — the standard for human organ transplants. Rejection risk depends on how well MHC (HLA) types match.
- Xenograft Tissue from a different species Full entry →: tissue from a different species (e.g., porcine heart valves). Vigorously rejected and mainly used for structures that are not living cells (like processed heart valves).
Why grafts are rejected: HLA mismatch
The human MHC molecules are called HLA (human leukocyte antigen) and are encoded by the most polymorphic genes in the genome — nearly everyone's set is unique. Recipient T cells recognize donor HLA as foreign and attack. The speed and mechanism divide rejection into three commonly taught patterns:
- Hyperacute rejection Rapid graft destruction in minutes–hours by pre-existing antibodies Full entry →: minutes to hours, driven by pre-existing antibodies in the recipient that bind donor blood vessels, causing rapid clotting and graft destruction. Avoided by blood-type and antibody screening (crossmatching) before transplant.
- Acute rejection T-cell-mediated graft attack over days–weeks Full entry →: days to weeks, driven mainly by T cells recognizing donor HLA. The most common form; usually controllable with immunosuppressive drugs.
- Chronic rejection Slow graft injury over months–years Full entry →: months to years, a slow, progressive injury to graft blood vessels and tissue, only partly understood and hard to treat.
Immunosuppression is the price of acceptance: drugs that dampen T-cell responses keep the graft alive but raise the risk of infection and cancer, which is why recipients need lifelong monitoring.
Graft-versus-host disease (GVHD)
In bone marrow or stem cell transplants, the situation flips: the graft contains immune cells, and those donor cells can attack the recipient's tissues (skin, gut, liver). This is graft-versus-host disease — the graft rejecting the host, not the host rejecting the graft.
Cancer immunology: tumors as "self gone wrong"
- Tumor antigens: cancer cells display molecules the immune system can recognize — mutated proteins unique to the tumor, overexpressed normal proteins, or viral proteins (e.g., from HPV). These make tumors theoretically attackable.
- Immune surveillance: the theory that immune cells routinely detect and destroy nascent cancers before they become clinically apparent.
- Immunoediting: the dynamic three-phase relationship between tumor and immune system — elimination (immune cells destroy the tumor), equilibrium (immune cells hold a dormant tumor in check), and escape (tumor variants emerge that evade or suppress the response).
- Evasion mechanisms: tumors downregulate MHC class I (hiding from CTLs — though this can make them targets for NK cells), secrete immunosuppressive molecules, recruit regulatory cells, and express PD-L1, which engages the PD-1 receptor on T cells and switches them off.
Immunotherapy concepts (educational overview)
- Checkpoint inhibitors: antibodies that block PD-1/PD-L1 interactions, "releasing the brakes" so T cells stay active against the tumor.
- CAR T cells: a person's own T cells are removed, engineered to express a receptor for a Tumor antigen A molecule on cancer cells that the immune system can recognize Full entry →, and infused back to attack the cancer.
- Monoclonal antibodies: lab-made antibodies that tag tumor cells for destruction or block growth signals.
- Cancer vaccines: aim to provoke an immune response against tumor antigens.
This is an evolving field: these approaches work dramatically for some people and some cancer types, and not at all for others — immunotherapies are not a universal cure.
Common Confusions
| Do Not Confuse | With | Difference |
|---|---|---|
| Autograft | Isograft | Autograft = same person; isograft = identical twin (genetically identical but a different person) |
| Hyperacute rejection | Acute rejection | Hyperacute: minutes–hours, preformed antibodies; Acute: days–weeks, T cells |
| Graft rejection | Graft-versus-host disease | Rejection: host attacks graft; GVHD: graft (donor immune cells) attacks host |
| Immune surveillance prevents all cancers | Surveillance is a theory with limits | Cancers still arise — immunoediting's "escape" phase explains how |
| Immunotherapy cures cancer | Immunotherapy helps some people with some cancers | Responses vary widely; the field is still evolving |
| Losing MHC I makes tumor cells invisible | It hides them from CTLs but exposes them to NK cells | MHC I loss trades one threat for another |
Eli explains
The same idea, in plain words
Explain it like I’m 10
Your immune cells check the ID cards (MHC badges) on every cell they meet. A transplanted organ carries a stranger's ID cards, so your guards attack it — doctors give "calming medicine" (immunosuppressants) so the guards leave the new organ alone. Cancer cells are troublemakers that wear your own ID cards, so your guards walk right past them. New treatments either tear off the disguise or tell the guards, "These are the bad guys — attack!"
Worked example
Walk through the transplant journey to see the concepts connect:
- Matching: A potential recipient is typed for blood group and HLA. A donor with the closest HLA match is preferred, because fewer mismatches means fewer foreign "ID cards" for recipient T cells to attack.
- Crossmatch: Recipient serum is tested against donor cells for pre-existing antibodies. A positive crossmatch predicts hyperacute rejection, so the transplant is not done — this screens out the fastest failure mode.
- Transplant and immunosuppression: The kidney is placed in the recipient, and immunosuppressive drugs are started to blunt T-cell responses. The recipient now lives with the trade-off: reduced rejection, increased susceptibility to infection.
- Monitoring for acute rejection: Days to weeks later, a rise in creatinine (a kidney function marker) might signal T-cell-mediated rejection. Biopsy confirms it; treatment increases immunosuppression (educational concept only — no protocols).
- Long term: Months to years later, chronic rejection can slowly damage the graft's blood vessels, a major reason grafts eventually fail even with good matching.
Now flip the same logic to cancer: the tumor is "self" carrying altered ID cards. Immunoediting explains why some tumors stay dormant for years (equilibrium) before emerging (escape), and why immunotherapies that remove the tumor's brakes (PD-L1) or give T cells better receptors (CAR T) can, in some cancers, convert escape back toward elimination.
Key takeaways
- Graft similarity hierarchy: autograft (self) > isograft (identical twin) > allograft (same species) > xenograft (different species).
- HLA = the human MHC; its genes are the most polymorphic in the genome, making matching central to transplant success.
- Rejection timing: hyperacute (minutes–hours, preformed antibodies), acute (days–weeks, T cells), chronic (months–years, slow vascular injury).
- GVHD: in bone marrow/stem cell transplants, the graft attacks the host.
- Immunosuppression is a trade-off: less rejection, more infection.
- Cancer immunology rests on tumor antigens and the immune surveillance theory.
- Immunoediting has three phases: elimination → equilibrium → escape.
- Tumors escape by downregulating MHC I, secreting suppressive molecules, and expressing PD-L1 to turn off T cells.
- Checkpoint inhibitors (PD-1/PD-L1 blockade) and CAR T cells are major educational examples of immunotherapy; results vary by cancer type.
Check yourself
6 review questions from the chapter. Try each one, then open the answer.
Arrange autograft, isograft, allograft, and xenograft from least to most immunogenic (most likely to be rejected).
Show answer
Autograft (self, least immunogenic) → isograft (identical twin) → allograft (same species, different genetics) → xenograft (different species, most immunogenic).
What drives hyperacute rejection, and how is it prevented before transplant?
Show answer
Pre-existing antibodies in the recipient bind donor blood vessels and trigger rapid clotting within minutes to hours. It is prevented by blood-type matching and antibody screening (crossmatch) before transplant.
In bone marrow transplantation, what does GVHD represent that ordinary rejection does not?
Show answer
GVHD is the graft attacking the host: the transplanted tissue contains donor immune cells that recognize the recipient's tissues as foreign. Ordinary rejection is the host attacking the graft.
Name the three phases of immunoediting and what happens in each.
Show answer
Elimination (immune cells destroy the tumor), equilibrium (immune cells hold a dormant tumor in check), and escape (tumor variants emerge that evade or suppress immunity and grow).
How does PD-L1 expression on a tumor cell protect it from T cells, and how does a Checkpoint inhibitor A drug concept that blocks PD-1/PD-L1 so T cells stay active Full entry → counteract that?
Show answer
PD-L1 on the tumor engages PD-1 on T cells, switching the T cells off. Checkpoint inhibitors are antibodies that block this interaction, so T cells remain activated and can attack the tumor.
Why is immunosuppression after a transplant described as a trade-off?
Show answer
Immunosuppressive drugs dampen T-cell responses to prevent rejection, but the same dampening weakens defenses against infection and cancer — the recipient trades rejection risk for infection risk.
Study tools & related lessonsKey vocabulary · Related
Key vocabulary
- Autograft
- Tissue moved from one site to another in the same person
- Isograft
- Tissue from an identical twin
- Allograft
- Tissue from a different person of the same species
- Xenograft
- Tissue from a different species
- HLA
- Human leukocyte antigen — the human MHC molecules
- Hyperacute rejection
- Rapid graft destruction in minutes–hours by pre-existing antibodies
- Acute rejection
- T-cell-mediated graft attack over days–weeks
- Chronic rejection
- Slow graft injury over months–years
- Graft-versus-host disease (GVHD)
- Donor immune cells in a transplant attack the recipient's tissues
- Tumor antigen
- A molecule on cancer cells that the immune system can recognize
- Immunoediting
- Elimination → equilibrium → escape: the evolving relationship between tumor and immune system
- Checkpoint inhibitor
- A drug concept that blocks PD-1/PD-L1 so T cells stay active
Sources & references
This lesson was adapted from the open educational references above; their licenses and attributions are preserved. See Copyright & Licensing.
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.